Total Payments
$11,162
2024 Payments
$1,513
Companies
13
Transactions
39
Medicare Patients
3,164
Medicare Billing
$885,211
Payment Breakdown by Category
Other$5,000 (44.8%)
Travel$2,843 (25.5%)
Food & Beverage$1,762 (15.8%)
Consulting$1,388 (12.4%)
Education$169.34 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $5,000 | 3 | 44.8% |
| Travel and Lodging | $2,843 | 2 | 25.5% |
| Food and Beverage | $1,762 | 14 | 15.8% |
| Consulting Fee | $1,388 | 1 | 12.4% |
| Education | $169.34 | 8 | 1.5% |
| Unspecified | $0 | 11 | 0.0% |
Payments by Type
General
$11,162
28 transactions
Ownership
$0
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $8,871 | 18 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,422 | 2 | $0 (2024) |
| Exelixis Inc. | $186.58 | 7 | $0 (2019) |
| Heron Therapeutics, Inc. | $173.76 | 1 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $125.00 | 1 | $0 (2024) |
| McKesson Specialty Care Distribution, LLC | $117.76 | 3 | $0 (2020) |
| Puma Biotechnology, Inc. | $81.02 | 1 | $0 (2018) |
| BeiGene USA, Inc. | $73.58 | 1 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $44.12 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $20.50 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,513 | 4 | Daiichi Sankyo Inc. ($1,388) |
| 2023 | $5,169 | 7 | Cornerstone Specialty Network LLC ($5,135) |
| 2022 | $73.58 | 3 | BeiGene USA, Inc. ($73.58) |
| 2021 | $30.80 | 4 | GlaxoSmithKline, LLC. ($18.88) |
| 2020 | $32.06 | 3 | E.R. Squibb & Sons, L.L.C. ($16.14) |
| 2019 | $216.60 | 6 | McKesson Specialty Care Distribution, LLC ($101.84) |
| 2018 | $4,071 | 9 | Cornerstone Specialty Network LLC ($3,736) |
| 2017 | $55.82 | 3 | Exelixis Inc. ($35.32) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 2024 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 2024 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 12/08/2023 | Cornerstone Specialty Network LLC | — | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| 11/17/2023 | Cornerstone Specialty Network LLC | — | Travel and Lodging | Cash or cash equivalent | $1,102.00 | General |
| 11/17/2023 | Cornerstone Specialty Network LLC | — | Food and Beverage | Cash or cash equivalent | $533.00 | General |
| 11/17/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $34.34 | General |
| 06/20/2023 | Cornerstone Specialty Network LLC | — | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| 2023 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 2023 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 09/10/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $73.58 | General |
| Category: Oncology | ||||||
| 2022 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 2022 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 10/13/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 2021 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 2021 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 07/21/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $16.14 | General |
| Category: Oncology | ||||||
| 02/11/2020 | McKesson Specialty Care Distribution, LLC | — | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| 2020 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 10/11/2019 | McKesson Specialty Care Distribution, LLC | — | Food and Beverage | Cash or cash equivalent | $85.00 | General |
| 04/02/2019 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $44.15 | General |
| Category: Oncology | ||||||
| 03/12/2019 | McKesson Specialty Care Distribution, LLC | — | Food and Beverage | Cash or cash equivalent | $16.84 | General |
| 03/09/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $44.12 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 729 | 3,191 | $833,201 | $132,968 |
| 2022 | 30 | 977 | 30,177 | $1.4M | $274,443 |
| 2021 | 22 | 797 | 25,101 | $894,397 | $245,641 |
| 2020 | 16 | 661 | 11,533 | $802,531 | $232,160 |
Total Patients
3,164
Total Services
70,002
Medicare Billing
$885,211
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 181 | 416 | $156,416 | $38,504 | 24.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 12 | 408 | $405,960 | $31,973 | 7.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 111 | $58,941 | $14,891 | 25.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 25 | 110 | $42,790 | $10,527 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 169 | $44,954 | $10,089 | 22.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $18,241 | $4,594 | 25.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 34 | 84 | $16,212 | $3,542 | 21.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 25 | $14,600 | $3,416 | 23.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 26 | $10,374 | $2,667 | 25.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 40 | $8,400 | $2,493 | 29.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 33 | 224 | $12,320 | $2,335 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $8,476 | $2,227 | 26.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 21 | 175 | $8,050 | $1,956 | 24.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 14 | 48 | $4,176 | $981.94 | 23.5% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 39 | $3,822 | $859.74 | 22.5% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 17 | 151 | $11,778 | $854.01 | 7.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 25 | $2,375 | $537.18 | 22.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 13 | 390 | $3,900 | $297.09 | 7.6% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 15 | 68 | $612.00 | $129.31 | 21.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 13 | 589 | $589.00 | $57.72 | 9.8% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 12 | 43 | $215.00 | $35.85 | 16.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 13 | 4,500 | $275,040 | $75,982 | 27.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2022 | 13 | 504 | $453,383 | $58,849 | 13.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 165 | 401 | $151,260 | $36,745 | 24.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 45 | 195 | $86,023 | $20,000 | 23.2% |
About Dr. Nseobong Ntukidem, MD
Dr. Nseobong Ntukidem, MD is a Medical Oncology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1447474523.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nseobong Ntukidem, MD has received a total of $11,162 in payments from pharmaceutical and medical device companies, with $1,513 received in 2024. These payments were reported across 39 transactions from 13 companies. The most common payment nature is "Honoraria" ($5,000).
As a Medicare-enrolled provider, Ntukidem has provided services to 3,164 Medicare beneficiaries, totaling 70,002 services with total Medicare billing of $885,211. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Columbus, OH
- Active Since 04/12/2007
- Last Updated 08/12/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1447474523
Products in Payments
- Enhertu (Drug) $1,388
- Cabometyx (Drug) $186.58
- SUSTOL (Drug) $173.76
- LIBTAYO (Biological) $125.00
- Nerlynx (Drug) $81.02
- BRUKINSA (Drug) $73.58
- Imbruvica (Drug) $44.12
- AFINITOR (Drug) $20.50
- ZEJULA (Drug) $18.88
- OPDIVO (Biological) $16.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Columbus
Taral Patel, Md, MD
Medical Oncology — Payments: $826,872
Medical Oncology $826,872
Tarek Chidiac, Md, MD
Medical Oncology — Payments: $800,968
Medical Oncology $800,968
Robert Wesolowski, Md, MD
Medical Oncology — Payments: $281,784
Medical Oncology $281,784
Dr. Christian Rolfo, Md, MD
Medical Oncology — Payments: $235,782
Medical Oncology $235,782
Yuanquan Yang, M.d, M.D
Medical Oncology — Payments: $111,221
Medical Oncology $111,221
Dr. Timothy Burns, M.d. Ph.d, M.D. PH.D
Medical Oncology — Payments: $109,695
Medical Oncology $109,695